TTrialPathMatch Me to Trials
← Back to trials
RecruitingDepression

ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression

Eligible age

18–60 yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.

Sponsor: Stanford University

You may qualify if…

  • ✓ In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • ✓ 1. Provision of signed and dated informed consent form
  • ✓ 2. Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3) and availability for the duration of the study
  • ✓ 3. Male or female
  • ✓ 4. Age 18-60 years
  • ✓ 5. Fluent and literate in English
  • ✓ 6. Meets DSM-5-TR diagnostic criteria for MDE (major depressive episode), and criteria for current or recurrent nonpsychotic MDD using the Mini International Neuropsychiatric Interview (MINI Plus)79
  • ✓ 7. A total score of 10 or higher on the PHQ-8 at initial screening, including:

You may not qualify if…

  • ✕ An individual who meets any of the following criteria will be excluded from participation in this study:
  • ✕ 1. Presence of one or more of the following conditions established via the participant's medical record and confirmed using the MINI Plus:
  • ✕ bipolar disorder (I, II, not otherwise specified, current or lifetime)
  • ✕ psychosis (current or lifetime)
  • ✕ moderate to severe alcohol or substance use disorders (current)
  • ✕ post-traumatic stress disorder (PTSD; current)
  • ✕ obsessive compulsive disorder (OCD; current or lifetime)
  • ✕ attention deficit hyperactivity disorder (ADHD; current or lifetime)

Where it's recruiting

California

Palo Alto

Illinois

Chicago

Source: ClinicalTrials.gov · NCT06408246 · last updated 2026-03-05